VivoSim Labs, Inc. Stock-Based Compensation
VivoSim Labs, Inc. (VIVS) reported Stock-Based Compensation of $91.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-12
- VivoSim Labs, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $91.00K, a 16.67% increase year-over-year.
- VivoSim Labs, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $86.00K, a 5.49% decline year-over-year.
- VivoSim Labs, Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $67.00K, a 48.46% decline year-over-year.
- VivoSim Labs, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $72.00K, a 53.55% decline year-over-year.
- VivoSim Labs, Inc. share-based payment arrangement, expense for fiscal 2026 was $303.00K, a 43.05% decline from fiscal 2025.
- VivoSim Labs, Inc. share-based payment arrangement, expense for fiscal 2025 was $532.00K, a 64.72% decline from fiscal 2024.
- VivoSim Labs, Inc. share-based payment arrangement, expense for fiscal 2024 was $1.51M, a 36.56% decline from fiscal 2023.
- VivoSim Labs, Inc. share-based payment arrangement, expense for fiscal 2023 was $2.38M, a 5.36% increase from fiscal 2022.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $91.00K 10-Q · filed 2026-08-12 | $177.00K derived: sum of 2 quarters · filed 2026-08-12 | $244.00K derived: sum of 3 quarters · filed 2026-08-12 | $316.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $86.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-14 | $153.00K derived: sum of 2 quarters · filed 2026-07-14 | $225.00K derived: sum of 3 quarters · filed 2026-07-14 | $303.00K 10-K · filed 2026-07-14 |
| 2025-12-31 | $67.00K 10-Q · filed 2026-02-11 | $139.00K derived: sum of 2 quarters · filed 2026-02-11 | $217.00K 10-Q · filed 2026-02-11 | $308.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-09-30 | $72.00K 10-Q · filed 2025-11-06 | $150.00K 10-Q · filed 2025-11-06 | $241.00K derived: sum of 3 quarters · filed 2026-08-12 | $371.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $78.00K 10-Q · filed 2026-08-12 | $169.00K derived: sum of 2 quarters · filed 2026-08-12 | $299.00K derived: sum of 3 quarters · filed 2026-08-12 | $454.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-14 | $221.00K derived: sum of 2 quarters · filed 2026-07-14 | $376.00K derived: sum of 3 quarters · filed 2026-07-14 | $532.00K 10-K · filed 2026-07-14 |
| 2024-12-31 | $130.00K 10-Q · filed 2026-02-11 | $285.00K derived: sum of 2 quarters · filed 2026-02-11 | $441.00K 10-Q · filed 2026-02-11 | $642.00K derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-09-30 | $155.00K 10-Q · filed 2025-11-06 | $311.00K 10-Q · filed 2025-11-06 | $512.00K derived: sum of 3 quarters · filed 2025-11-06 | $669.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $156.00K 10-Q · filed 2025-08-12 | $357.00K derived: sum of 2 quarters · filed 2025-08-12 | $514.00K derived: sum of 3 quarters · filed 2025-08-12 | $1.19M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $201.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-05 | $358.00K derived: sum of 2 quarters · filed 2025-06-05 | $1.03M derived: sum of 3 quarters · filed 2025-06-05 | $1.51M 10-K · filed 2025-06-05 |
| 2023-12-31 | $157.00K 10-Q · filed 2025-02-19 | $832.00K derived: sum of 2 quarters · filed 2025-02-19 | $1.31M 10-Q · filed 2025-02-19 | $1.81M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-09-30 | $675.00K 10-Q · filed 2024-11-08 | $1.15M 10-Q · filed 2024-11-08 | $1.65M derived: sum of 3 quarters · filed 2024-11-08 | $2.19M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $475.00K 10-Q · filed 2024-08-05 | $975.00K derived: sum of 2 quarters · filed 2024-08-05 | $1.52M derived: sum of 3 quarters · filed 2024-08-05 | $2.19M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-31 | $1.04M derived: sum of 2 quarters · filed 2024-05-31 | $1.72M derived: sum of 3 quarters · filed 2024-05-31 | $2.38M 10-K · filed 2024-05-31 |
| 2022-12-31 | $544.00K 10-Q · filed 2024-02-08 | $1.22M derived: sum of 2 quarters · filed 2024-02-08 | $1.88M 10-Q · filed 2024-02-08 | $2.70M derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-09-30 | $673.00K 10-Q · filed 2023-11-09 | $1.33M 10-Q · filed 2023-11-09 | $2.16M derived: sum of 3 quarters · filed 2023-11-09 | $2.75M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $660.00K 10-Q · filed 2023-08-10 | $1.49M derived: sum of 2 quarters · filed 2023-08-10 | $2.08M derived: sum of 3 quarters · filed 2023-08-10 | $2.50M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $827.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-14 | $1.42M derived: sum of 2 quarters · filed 2023-07-14 | $1.84M derived: sum of 3 quarters · filed 2023-07-14 | $2.26M 10-K · filed 2023-07-14 |
| 2021-12-31 | $588.00K 10-Q · filed 2023-02-09 | $1.01M derived: sum of 2 quarters · filed 2023-02-09 | $1.43M 10-Q · filed 2023-02-09 | $1.72M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-09-30 | $426.00K 10-Q · filed 2022-11-10 | $841.00K 10-Q · filed 2022-11-10 | $1.13M derived: sum of 3 quarters · filed 2022-11-10 | $1.33M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $415.00K 10-Q · filed 2022-08-11 | $702.00K derived: sum of 2 quarters · filed 2022-08-11 | $908.00K derived: sum of 3 quarters · filed 2022-08-11 | $5.05M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $287.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-10 | $493.00K derived: sum of 2 quarters · filed 2022-06-10 | $4.63M derived: sum of 3 quarters · filed 2022-06-10 | $5.56M 10-K · filed 2022-06-10 |
| 2020-12-31 | $206.00K 10-Q · filed 2022-02-14 | $4.34M derived: sum of 2 quarters · filed 2022-02-14 | $5.27M 10-Q · filed 2022-02-14 | $5.67M derived: sum of 4 quarters · filed 2022-02-14 |
| 2020-09-30 | $4.14M 10-Q · filed 2021-11-08 | $5.06M 10-Q · filed 2021-11-08 | $5.46M derived: sum of 3 quarters · filed 2021-11-08 | $6.71M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $925.00K 10-Q · filed 2021-08-06 | $1.32M derived: sum of 2 quarters · filed 2021-08-06 | $2.58M derived: sum of 3 quarters · filed 2021-08-06 | $3.81M derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-06-15 | $1.65M derived: sum of 2 quarters · filed 2021-06-15 | $2.89M derived: sum of 3 quarters · filed 2021-06-15 | $4.11M 10-K · filed 2021-06-15 |
| 2019-12-31 | $1.25M 10-Q · filed 2021-02-08 | $2.49M derived: sum of 2 quarters · filed 2021-02-08 | $3.71M 10-Q · filed 2021-02-08 | $4.99M derived: sum of 4 quarters · filed 2021-02-08 |
| 2019-09-30 | $1.24M 10-Q · filed 2020-11-05 | $2.46M 10-Q · filed 2020-11-05 | $3.74M derived: sum of 3 quarters · filed 2020-11-05 | $5.10M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $1.22M 10-Q · filed 2020-08-10 | $2.50M derived: sum of 2 quarters · filed 2020-08-10 | $3.86M derived: sum of 3 quarters · filed 2020-08-10 | $5.13M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-28 | $2.64M derived: sum of 2 quarters · filed 2020-05-28 | $3.91M derived: sum of 3 quarters · filed 2020-05-28 | $5.19M 10-K · filed 2020-05-28 |
| 2018-12-31 | $1.36M 10-Q · filed 2020-02-10 | $2.63M derived: sum of 2 quarters · filed 2020-02-10 | $3.91M 10-Q · filed 2020-02-10 | $5.21M derived: sum of 4 quarters · filed 2020-02-10 |
| 2018-09-30 | $1.27M 10-Q · filed 2019-11-07 | $2.55M 10-Q · filed 2019-11-07 | $3.86M derived: sum of 3 quarters · filed 2019-11-07 | $5.11M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $1.28M 10-Q · filed 2019-08-08 | $2.58M derived: sum of 2 quarters · filed 2019-08-08 | $3.83M derived: sum of 3 quarters · filed 2019-08-08 | $6.13M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2019-06-03 | $2.55M derived: sum of 2 quarters · filed 2019-06-03 | $4.85M derived: sum of 3 quarters · filed 2019-06-03 | $6.90M 10-K · filed 2019-06-03 |
| 2017-12-31 | $1.25M 10-Q · filed 2019-02-07 | $3.55M derived: sum of 2 quarters · filed 2019-02-07 | $5.60M 10-Q · filed 2019-02-07 | $7.45M derived: sum of 4 quarters · filed 2019-02-07 |
| 2017-09-30 | $2.30M 10-Q · filed 2018-11-08 | $4.35M 10-Q · filed 2018-11-08 | $6.20M derived: sum of 3 quarters · filed 2018-11-08 | $8.22M derived: sum of 4 quarters · filed 2018-11-08 |
| 2017-06-30 | $2.05M 10-Q · filed 2018-08-09 | $3.90M derived: sum of 2 quarters · filed 2018-08-09 | $5.92M derived: sum of 3 quarters · filed 2018-08-09 | $8.02M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | $1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2018-05-31 | $3.87M derived: sum of 2 quarters · filed 2018-05-31 | $5.96M derived: sum of 3 quarters · filed 2018-05-31 | $7.39M 10-K · filed 2018-05-31 |
| 2016-12-31 | $2.02M 10-Q · filed 2018-02-08 | $4.11M derived: sum of 2 quarters · filed 2018-02-08 | $5.54M 10-Q · filed 2018-02-08 | |
| 2016-09-30 | $2.09M 10-Q · filed 2017-11-09 | $3.52M 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | $1.43M 10-Q · filed 2017-08-09 | |||
| 2016-03-31 | $8.56M 10-K · filed 2018-05-31 | |||
| 2015-03-31 | $7.02M 10-K · filed 2017-06-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |